Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 2, 2012, Pages 171-179

  Aapro, Matti ^a   Cornes, Paul ^b   Abraham, Ivo ^c,d  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^c UNIVERSITY OF ARIZONA   (United States)

^d Matrix45   (United States)

Author keywords

biosimilars; cost savings; cost efficiency; febrile neutropenia; Filgrastim; G CSF; neutropenia; pegfilgrastim

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE COMPARISON; FEBRILE NEUTROPENIA; FRANCE; GERMANY; HUMAN; INCIDENCE; ITALY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; SPAIN; TREATMENT DURATION; UNITED KINGDOM;

BIOSIMILAR PHARMACEUTICALS; COST-BENEFIT ANALYSIS; EUROPE; EUROPEAN UNION; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; NEUTROPENIA; RECOMBINANT PROTEINS;

EID: 84871355839     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155211407367     Document Type: Article

References (39)

1. Lalami Y, Paesmans M, Muanza F, et al. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol. 2006 ; 17: 507-514
2. Lalami Y, Paesmans M, Aoun M, et al. A prospective randomized evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Support Care Cancer. 2004 ; 12: 725-730
3. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005 ; 10: 427-437
4. Kuderer N, Dale D, Crawford J, Cosler L, Lyman G. Impact of primary prophylaxis with granulocyte colony-stimulating factor or febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007 ; 25: 3158-3167
5. Paessens B, von Schilling C, Berger K, et al. Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients. Ann Oncol. :
6. Calhoun E, Chang CH, Welshman E, Cella D. The impact of chemotherapy delays on quality of life in patients with cancer. J Support Oncol. 2004 ; 2: 64-65
7. Wingard JR, Elmongy M. Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol. 2009 ; 72: 144-154
8. Raposo CG, Marin AP, Barón MG. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia. Clin Translat Oncol. 2006 ; 8: 729-734
9. Summary of Product Characteristics - Zarzio®. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000917/WC500046525.pdf. (accessed 10 November 2010)
10. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast Cancer. JClin Oncol. 2002 ; 20: 727-731
11. Green MD, Koebl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003 ; 14: 29-35
12. Siena S, Piccart MJ, Holmes Fa, et al. A combined analysis of two pivotal randomized trials of single dose pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 2003 ; 19: 715-724
13. von Minckwitz G, Kümmel S, du Bois A, et al. Pegfilgrastim + ciproflaxin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer. Results from the GEPATRIO study. Ann Oncol. 2008 ; 19: 292-298
14. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled Phase III study. J Clin Oncol. 2005 ; 23: 1178-1184
15. Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007 ;: 2283-2295
16. Klastersky J, Awad A. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: pegulated versus standard myeloid colony stimulating factors. Do we have a choice?. Crit Rev Oncol Hematol. 2010 ;:
17. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006 ; 42: 2433-2453
18. Crawford J, Caserta F, Roila F, et al. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol. 2010 ; 21: v252 - v256
19. de Naurois J, Novitzky-Basso, Gill MJ, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010 ; 21: v257 - v260
20. National Comprehensive Cancer Network. Myeloid growth factors. Practice guidelines in oncology v.1.2010. Available at http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp#supportive. (accessed 27 October 2010)
21. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 ; 24: 3187-3205
22. Liu Z, Doan QV, Malin J, Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer inthe UK. Appl Health Econ Health Policy. 2009 ; 7: 193-205
23. Borget I, Di Palma M, Leonard R. Pegfilgrastim - a health economic model to assess overall cost effectiveness. Eur J Hosp Pharm Pract. 2009 ; 15: 58-61
24. Sehouli J, Goertz A, Steinle T, et al. Pegfilgrastim vs. Filgrastim zur Primärprophylaxe der febrile Neutropenie bei Brustkrebspatientinnen nach Chemotherapie: eine Kosten-Effektivitäts-Analyse für Deutschland. Dtsch Med Wochenschr. 2010 ; 135: 385-389
25. Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther. 2009 ; 31: 1092-1104
26. Danova M, Chiroli S, Rosti G, Doan QV. Cost-effectiveness of pegfilgrastim versus six days of filgrastime for preventing febrile neutropenia in breast cancer patients. Tumori. 2009 ; 95: 219-226
27. Falandry C, Campone M, Cartron X, et al. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer. 2010 ; 46: 2389-2398
28. Almenar D, Mayans D, Juan O, et al. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN study. Eur J Cancer Care. 2009 ; 18: 280-286
29. Weycker D, Hackett J, Edelsberg J, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?. Ann Pharmacother. 2006 ; 40: 402-407
30. Eurostat. 'Tables, Graphs, and Maps Interface'. http://epp.eurostat.ec. europa.eu/tgm/table.do?tab=table&language=en&pcode=tps00001& tableSelection=1&footnotes=yes&labeling=labels&plugin=1.
31. www.lauer-fischer.de. (accessed 13 October 2010)
32. www.codage.ext.cnamts.fr. (accessed 13 October 2010)
33. www.theriaque.org. (accessed 13 October 2010)
34. www.codifa.it. (accessed 13 October 2010)
35. www.portalfarma.com. (accessed 13 October 2010)
36. www.healthcarerepublic.com. (accessed 13 October 2010)
37. www.oanda.com/currency/historical-rates. (accessed 9 October 2010)
38. GascónPAaproMLudwigH. Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Crit Rev Oncol Hematol. E-publication ahead of print. http://dx.doi.org/10.1016/j.critrevonc.2010.01. 014. Last accessed 14 October 2010.
39. Aapro M, MacDonald K, Van Erps J, et al. Managing cancer-related anemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study. Eur J Cancer. 2009 ; 45: 8-11